FDA issues Viagra ad warning letter

Share this article:
The FDA issued a warning letter to Pfizer for not mentioning the risks of impotence pill Viagra in a video ad on CNN.com.
 
The 30-second video showed a group of musicians singing “Viva Viagra” in a song about the benefits of the drug.

Pfizer said in published reports that a technical issue with the CNN website prevented the risk information from being displayed on a banner to accompany the video and that it has since pulled the ad.

“Pfizer discovered the error, notified the website of the error, and our understanding was that the website corrected its error immediately,” the company said in a statement.

Drugmakers are required to mention a drug's negative side effects in any advertisement that highlights benefits. Viagra's label warns of potential risks to patients with existing heart conditions as well as reported headaches and abnormal vision.

The FDA warning letter was dated April 16 and posted to the FDA's website April 21.

In the letter, DDMAC director Thomas Abrams wrote the Viagra ad “raises public health and safety concerns through its complete omission of risk information for Viagra.”
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...